HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

endothelin-converting enzyme

Subscribe to New Research on endothelin-converting enzyme

pH optimum 3.5; cathepsin D-like aspartic protease; inhibited by pepstatin; ECE-1 is a metalloproteinase that catalyzes proteolytic activation of big endothelin-1; RefSeq NM_001397 (ECE1, human), NM_199307 (Ece1, mouse); NM_139293 (Ece2, mouse); NM_014693 (ECE2, human)

Also Known As:

ECE-1 protein, human; ECE-1beta; ECE-2; ECE-2 protein; ECE-2 protein, human; ECE1 protein, human; ECE2 protein, human; Ece1 protein, mouse; Ece2 protein, mouse; Endothelin-converting enzyme 1; Endothelin-converting enzyme 2; endothelin converting enzyme; endothelin converting enzyme 1, human; endothelin converting enzyme 1, mouse; endothelin converting enzyme 2, human; endothelin converting enzyme 2, mouse; endothelin converting enzyme II; endothelin converting enzyme-1a; endothelin converting enzyme-2; endothelin-converting enzyme-1b; endothelin-converting enzyme-2; endothelin-converting metalloprotease 2; metalloprotease ECE-2

Networked: 137 relevant articles (6 outcomes, 21 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Enzymes and Coenzymes
- Enzymes: 34502
  - Hydrolases: 639
    - Peptide Hydrolases: 7577

Experts

1.	Jeng, Arco Y: 9 articles (11/2010 - 08/2002)
2.	Kwan, Aij-Lie: 6 articles (03/2007 - 08/2002)
3.	Hocher, Berthold: 4 articles (06/2011 - 11/2004)
4.	Naruko, Takahiko: 4 articles (03/2008 - 05/2004)
5.	Tanzawa, Kazuhiko: 4 articles (03/2008 - 01/2003)
6.	Ueda, Makiko: 4 articles (03/2008 - 05/2004)
7.	Ikura, Yoshihiro: 4 articles (03/2008 - 05/2004)
8.	Kassell, Neal F: 4 articles (03/2007 - 08/2002)
9.	Wu, Shu-Chuan: 4 articles (03/2007 - 08/2002)
10.	Matsumura, Yasuo: 3 articles (05/2011 - 09/2008)

Related Diseases

1.	Muscle Spasticity (Spastic) 04/01/2003 - "However, relaxations to chelerythrine were not significantly greater in endothelin-1 constricted spastic vessels initially relaxed with the endothelin converting enzyme inhibitor, phosphoramidon, as compared to endothelin-1 constricted control vessels. " 06/01/2002 - "However, relaxations to Y-27632 were not significantly greater in endothelin-1 constricted spastic vessels initially relaxed with the endothelin converting enzyme inhibitor, phosphoramidon, as compared to endothelin-1 constricted control vessels. "
2.	Hypertension (High Blood Pressure) 09/29/2009 - "Recent studies have identified a polymorphism in the endothelin-converting enzyme (ECE)-1b promoter (-338C/A) that is strongly associated with hypertension in women. " 08/01/1998 - "The hypotensive effects of endothelin converting enzyme inhibitors and endothelin receptor antagonists should be useful in the treatment of hypertension and related diseases. " 09/01/2013 - "Combined endothelin-converting enzyme and neutral endopeptidase inhibition could provide a new approach to hypertension in this high-risk population. " 06/01/2001 - "Chronic vasopeptidase inhibition restores endothelin-converting enzyme activity and normalizes endothelin levels in salt-induced hypertension." 10/01/2000 - "The results of experimental and human studies with antagonists of endothelin receptors and endothelin-converting enzyme blockers also support the role of endothelin in the pathogenesis of hypertension. "
3.	Ischemia 02/01/2011 - "As ET-1 is generated from big ET-1 via endothelin-converting enzyme (ECE), ischemia/reperfusion-induced cardiac injury may be exacerbated by exogenous big ET-1. " 05/01/2011 - "We have recently shown that an appropriate amount of exogenous big endothelin-1 (ET-1) has beneficial effects on ischemia-/reperfusion-induced norepinephrine overflow and cardiac dysfunction in rat hearts and that these effects occur through a conversion to ET-1 by endothelin-converting enzyme and following stimulation of ETB receptor. " 11/01/2002 - "To evaluate the effect of the combination of N-acetylcysteine (NAC), a potent antioxidant, sodium nitroprusside (SNP), a nitric oxide donor, and phosphoramidon (P), an endothelin converting enzyme inhibitor, on tissue protection against ischemia-reperfusion injury, we studied the biochemical and morphological changes due to 90 min of renal ischemia-reperfusion in the rat model. " 09/04/2008 - "The aim of this study was to investigate the role of endogenously generated endothelin-1 in ischemia/reperfusion-induced norepinephrine overflow and cardiac dysfunction using a nonselective prototype of endothelin-converting enzyme (ECE) inhibitor, phosphoramidon, and a selective ECE inhibitor, SM-19712 (4-chloro-N-[[(4-cyano-3-methyl-1-phenyl-1H-pyrazol-5-yl)amino]carbonyl]benzenesulfonamide, monosodium salt). " 10/01/1998 - "In this study, the effects of BQ123 (an ET(A) receptor antagonist), bosentan (a nonselective ET(A)-ET(B) antagonist), and phosphoramidon (an endothelin converting enzyme inhibitor) were investigated on intestinal mucosal lesion formation and changes in tissue PGE2 and LTC4 levels due to intestinal ischemia-reperfusion (I/R) injury in rats. "
4.	Pulmonary Hypertension (Ayerza Syndrome) 09/01/2003 - "We hypothesized that increased ET-1 levels induce pulmonary hypertension during group B Streptococcus (GBS) infusion, and this can be attenuated by the administration of an endothelin-converting enzyme inhibitor (ECEI). " 09/01/2003 - "The role of endothelin converting enzyme inhibition during group B streptococcus-induced pulmonary hypertension in newborn piglets." 11/01/1999 - "ET-1 has been noted in high concentrations in some clinical cases and experimental models of pulmonary hypertension, coupled with ET-1 receptors' modulation and altered endothelin converting enzyme activities, suggesting their active role in both arteriolar vasoconstriction and occlusion. " 08/01/1995 - "Blockade of endothelin-converting enzyme reduces pulmonary hypertension after cardiopulmonary bypass and circulatory arrest." 07/01/2008 - "[Chronic theatment with an endothelin-converting enzyme inhibitor reduces the development of hypoxia-induced pulmonary hypertension in rat]."
5.	Reperfusion Injury 07/01/2001 - "Protective role of an endothelin-converting enzyme inhibitor (FR901533) in hepatic ischemia/reperfusion injury." 01/01/1997 - "Phosphoramidon, an endothelin converting enzyme inhibitor attenuates local gastric ischemia-reperfusion injury in rats." 01/01/1997 - "We have investigated the effects of endothelin converting enzyme inhibition on local gastric ischemia-reperfusion injury in rats by using two metalloprotease inhibitors, phosphoramidon and thiorphan. " 11/01/2002 - "To evaluate the effect of the combination of N-acetylcysteine (NAC), a potent antioxidant, sodium nitroprusside (SNP), a nitric oxide donor, and phosphoramidon (P), an endothelin converting enzyme inhibitor, on tissue protection against ischemia-reperfusion injury, we studied the biochemical and morphological changes due to 90 min of renal ischemia-reperfusion in the rat model. "

Related Drugs and Biologics

1.	phosphoramidon
2.	Endothelin-1 (Endothelin 1)
3.	Neprilysin (Neutral Endopeptidase)
4.	Endothelin Receptors (Endothelin Receptor)
5.	chelerythrine
6.	Nitroprusside (Sodium Nitroprusside)
7.	Nitric Oxide (Nitrogen Monoxide)
8.	Acetylcysteine (Siran)
9.	Y 27632
10.	CGS 26303

Related Therapies and Procedures

1.	Transplants (Transplant)
2.	Intravenous Infusions
3.	Microspheres (Microsphere)
4.	Immunomodulation
5.	Homologous Transplantation (Allograft)